Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States

Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States

<p>Simulation results using our EMT network model.</p>

Gardado en:

Detalles Bibliográficos
Autor Principal:	Namhee Kim (14963603) (author)
Outros autores:	Chae Young Hwang (14963606) (author), Taeyoung Kim (14963609) (author), Hyunjin Kim (14963612) (author), Kwang-Hyun Cho (14953801) (author)
Publicado:	2025
Subjects:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Computational Methods Mathematical modeling Drug Targets Gene Regulation Oncogenes & Tumor Suppressors Suppressors of metastasis Systems Biology
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares

Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
por: Namhee Kim (14963603)
Publicado: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
por: Gwo Yaw Ho (14961416)
Publicado: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
por: Renumathy Dhanasekaran (14962092)
Publicado: (2025)

Wind Reversals During Morning and Evening Transitions in a Small Valley
por: Rui Zhang (20177106)
Publicado: (2025)

Illustration of dynamic real-time obstacle avoidance.
por: Meiqing Xu (8502255)
Publicado: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
por: Ana Vujovic (15207479)
Publicado: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
por: Yuanqing Ma (15052437)
Publicado: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
por: Yufang Bao (15386826)
Publicado: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
por: Yufang Bao (15386826)
Publicado: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
por: Yufang Bao (15386826)
Publicado: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
por: Yufang Bao (15386826)
Publicado: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
por: Yufang Bao (15386826)
Publicado: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
por: Yemin Wang (17315078)
Publicado: (2025)

Supplementary Table 1 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
por: Qin-Shu Li (16990832)
Publicado: (2025)

Supplementary Table 2 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
por: Qin-Shu Li (16990832)
Publicado: (2025)

Supplementary Table 1 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 2 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 3 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 4 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 6 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 7 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 8 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Supplementary Table 9 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
por: Chun-Miao Deng (15618965)
Publicado: (2025)

Table S7 from Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver Variants
por: Jakob Landau (14962529)
Publicado: (2025)

Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
por: Guillaume Davidson (14964069)
Publicado: (2025)

Cannot write session to /tmp/vufind_sessions/sess_me680fe77p421i56v92vl65i56